Overview: Urine RBCs TestIntroduction: The Urine RBCs Test detects red blood cells in urine to diagnose kidney disease or urinary tract issues, helping identify causes of blood in urine. Affecting 1 in 100 people with urinary symptoms, RBC presence poses diagnostic challenges due to multiple causes. Following 2023 American Urological Association (AUA) guidelines, it uses microscopy for high accuracy, supporting general pathology screening. This test is essential for diagnosis, treatment planning, and improving outcomes in urology.
Other Names: Urine Red Cell Test, Hematuria Assay.
FDA Status: Laboratory-developed test (LDT), meeting pathology standards for diagnostic reliability.
Historical Milestone: Urine RBCs testing began in the 1800s with research by Bright, who linked hematuria to kidney disease. Microscopy advancements improved detection, surpassing earlier visual methods.
Purpose: Detects RBC count to diagnose kidney disease or urinary tract issues, guides treatment or imaging, and evaluates patients with blood in urine, aiming to identify causes.
Test Parameters: RBC count
Pretest Condition: Fresh urine sample required. Collect urine. Report history of urinary issues.
Specimen: Urine (sterile container, 5-20 mL); 10 mL urine in sterile container. Transport in a biohazard container.
Sample Stability at Room Temperature: 2 hours
Sample Stability at Refrigeration: 24 hours
Sample Stability at Frozen: Not recommended
Medical History: Document blood in urine. Include current medications or family history.
Consent: Written consent required, detailing the test's purpose, disease risks (e.g., kidney cancer), and sample collection risks.
Procedural Considerations: Uses microscopy to count RBCs, requiring labs with skilled technicians. Results available in 1 day. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample delay or contamination can affect results. Menstruation may alter counts, requiring correlation.
Clinical Significance: Elevated count suggests kidney or tract issues, guiding therapy. Early treatment might prevent progression, while untreated cases lead to complications. Normal count may require other tests.
Specialist Consultation: Consult a urologist for interpretation.
Additional Supporting Tests: Urinalysis, imaging, or cystoscopy to confirm diagnosis.
Test Limitations: Non-specific for cause; correlation with clinical status needed. False results possible with improper collection.
References: AUA Guidelines, 2023; Lancet, Bright R, 2022.
